Indian Journal Watch: 4 November 2026

Indian Journal Watch, InfectionIndia.com

Indian Journal Watch

4 November 2026

Peer-reviewed microbiology, infectious disease, AMR and infection-control papers from India and South Asia, published or added to PubMed from 2 to 3 November 2026.

Lead articles

Vector-borne disease · Public health surveillance · Malaria Journal

Malaria in an informal settlement of a socioeconomically disadvantaged population in Rajasthan, a non-endemic state of India, 2024: an epidemiological investigation

Malaria Journal · doi:10.1186/s12936-026-06173-8 · PubMed 42972346

What
An outbreak investigation by the India Epidemic Intelligence Service, National Centre for Disease Control (NCDC), New Delhi, into three suspected malaria deaths reported in November 2024 from an informal settlement in Sirohi district, Rajasthan, a malaria non-endemic state with fewer than 1 case per 1000 population.
Design
Verbal autopsies of the three deceased children, a house-to-house survey for suspected cases (fever between 11 October and 10 December 2024), confirmation by rapid antigen test or blood smear microscopy, larval and adult mosquito collection, and observation of slide preparation and microscope quality at the nearest health facility.
Key findings
All three deceased children (aged two, five and 11 years) were siblings with fever lasting 6-10 days; two died at home untreated and one was confirmed as P. falciparum in hospital. Among 752 residents, 41 suspected cases were identified and 21 confirmed (18 Pf, 3 Pv; attack rate 2.8%); six needed hospitalisation (all Pf), and the case fatality rate was 14.3% (3/21). Larval breeding was found in six of 160 water bodies. Of 278 adult Anopheles collected, An. subpictus (29.3%), An. stephensi (20%), An. fluviatilis (19%) and An. culicifacies (12.5%) predominated. Most cases (95%) slept outdoors without nets.
Limitations
A single-settlement field investigation; the authors describe contributing factors as probable rather than established.
Relevance to India
Microscopy facilities were non-functional and incorrect slide-preparation practices were observed; the settlement was unmapped and excluded from routine surveillance and control. The team trained field staff, carried out source reduction and community awareness, and recommended strengthening laboratory diagnostics.

Antimicrobial resistance · Laboratory · MicrobiologyOpen

In-Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Carbapenem-Resistant Gram-Negative Isolates at a Tertiary Care Hospital in Lahore, Pakistan: A Cross-Sectional Study

MicrobiologyOpen · doi:10.1002/mbo3.70449 · PubMed 42975008

What
A laboratory-based cross-sectional study from National Hospital and Medical Centre and Services Institute of Medical Sciences, Lahore, assessing the in-vitro activity of ceftazidime-avibactam (CAZ-AVI) and comparator agents against carbapenem-resistant Gram-negative isolates in Pakistan.
Design
Consecutive non-duplicate carbapenem-resistant isolates from a tertiary care centre (December 2024 to May 2025) were tested by MIC and disc diffusion with CLSI interpretation. The primary outcome was CAZ-AVI susceptibility with exact binomial 95% CIs; Fisher’s exact test, McNemar’s test and multivariable logistic regression were used.
Key findings
Of 210 isolates, 200 had CAZ-AVI results; susceptibility was 70.5% (141/200; 95% CI 63.7-76.7). It varied by sample source (p = 0.008), from 81.2% in blood cultures to 38.5% (5/13) in other specimens, but not by organism, department, age or gender. CAZ-AVI susceptibility exceeded gentamicin, ciprofloxacin, piperacillin-tazobactam and trimethoprim-sulfamethoxazole, was similar to amikacin, and was lower than colistin, fosfomycin and tigecycline. Among 59 CAZ-AVI-resistant isolates, colistin (94.5%), fosfomycin (92.9%), tigecycline (79.5%) and chloramphenicol (76.7%) were most active.
Limitations
Single centre; no molecular characterisation. The authors describe metallo-β-lactamase production as a plausible but unconfirmed explanation for resistance, and the sample-source estimate (adjusted OR 0.18, 95% CI 0.05-0.68) as imprecise.
Relevance to South Asia
Metallo-β-lactamases, which CAZ-AVI does not inhibit, are common in South Asia. The authors state the findings support surveillance and susceptibility-guided rather than empirical use, and call for molecular characterisation and evaluation of CAZ-AVI plus aztreonam.

More from the journals

Antimicrobial resistance & stewardship

Vector-borne, parasitic & zoonotic

Tuberculosis

Mycology

Virology & diagnostics

IPC, sepsis & clinical infection

Items are summaries of published abstracts and are not clinical advice. Readers should consult the original article. Figures are quoted as reported in each abstract.

Leave a Reply

Your email address will not be published. Required fields are marked *